Atopic Dermatitis | Emerging Therapies | Eucrisa | US is a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data collected at 1, 6, and 12 months post-commercial launch from surveys of U.S. dermatologists. Along with awareness of, sources of familiarity with, and perceptions related to Eucrisa, the research assesses trial, adoption, and usage, including anticipated future trends, of Eucrisa. We also explore Pfizer’s promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other previously launched immune agents.
What you will learn in this content:
- What is U.S. dermatologists' awareness of and familiarity with Eucrisa, and what are their perceptions of this product?
- Among prescribers, for which patients are they prescribing Eucrisa, what are the reasons for prescribing, and how satisfied are they with Eucrisa?
- What are the promotional messages and activities that Pfizer is employing in support of the Eucrisa launch?
- How do prescribers and nonprescribers compare across key metrics?
- How is the trial and adoption of Eucrisa tracking compared with other recent product launches in the AD market?
Methodology: ~75 U.S. dermatologists complete a 30-minute online quantitative survey with several open-ended questions for qualitative feedback.
Key drugs: Eucrisa
Key companies: Pfizer
Related reports: Atopic Dermatitis | Disease Landscape and Forecast | US/EU/Japan, Atopic Dermatitis | Unmet Need | US/EU, Atopic Dermatitis | Access and Reimbursement | US, Atopic Dermatitis | Access and Reimbursement | EU5, Atopic Dermatitis | Current Treatment | EU5
- Atopic Dermatitis/Atopic Eczema - Emerging Therapies - Eucrisa Launch Tracking Wave 2 (US)
Author(s): Matthew W. Scutcher, MEng PhD; Emily Schriner, MPH
Matthew Scutcher is Therapy Leader for the Immune & Inflammatory research team at DRG.
In this role, he leads a team of 13 Research Associates, Business Insights Analysts and Directors responsible for analyzing some of the largest and most dynamic markets in the pharmaceutical industry
He has been with DRG since 2009 and holds a Ph.D. from University College London and a Master’s degree in Chemical Engineering from Imperial College London.
Emily is an Business Insights Analyst with the Immune and Inflammatory Disorders team at Decision Resources Group. She has authored several content pieces for immune market research reports and keeps the team up-to-date on the immune markets through research on patent life, pricing, and pipeline information.
Emily earned her Master of Public Health in Nutrition at West Chester University, focusing on research, analysis, and program development. She completed an internship at Nemours Health Network in Wilmington, Delaware where she did nutrition education development and primary research on program evaluation before initially joining DRG as a data analyst on the Research Analytics Team.